White Paper

From Research To Commercial Quantities: A Seamless Supply Of Oligonucleotides

Aji Feature

Oligonucleotides are poised for high growth over the next five years, with the market doubling in value during this time frame. This growth is driven by the high application potential of oligonucleotides to be used in the treatments of a variety of medical conditions, the growing number of FDA approved oligonucleotide drugs, an increased focus on customized or personalized medicine, and a continued emphasis on the development of therapeutics for rare disease.

As a result, contract development and manufacturing organizations (CDMOs), such as Ajinomoto Bio-Pharma Services, are seeing increased demand for oligonucleotide synthesis. However, with this developing market comes some considerable challenges for drug manufacturers in the ability to cost-effectively, quickly and easily scale from research amounts to commercial needs.

In this white paper, we will discuss how Ajinomoto Bio-Pharma Services meets this seamless supply challenge by providing development, scale-up and synthesis capabilities of research to commercial quantities of customized oligonucleotides.

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Outsourced Pharma

Ajinomoto Bio-Pharma Services